Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 3Neoplasms 3Breast Neoplasms 3Pain 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Incontinence, Stress 1Urinary Incontinence 1Sleep Initiation and Maintenance Disorders 1Postoperative Urinary Retention (POUR) 1Postoperative Nausea and Vomiting 1Postoperative Complications 1PGS 1Opioid-Induced Constipation 1Neuropathy, Painful 1Neuralgia 1Multiple Endocrine Neoplasia Type 1 1Low Anterior Resection Syndrome 1Fatigue 1Depression 1Cancer Pain 1Anxiety Disorders 1Agnosia 1

Interventions

phenazine 1Surveys and Questionnaires 1Sufentanil 1Promethazine 1Ondansetron 1Famotidine 1Electroacupuncture 1Electric Stimulation 1Diphenhydramine 1Dexamethasone 1Calcium Dobesilate 1Anesthesia, General 1((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Postoperative Nausea and Vomiting × Electroacupuncture × 1 year × Clear all
NCT07515027 2026-04-13

Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery

Shanghai Chest Hospital

Phase NA Recruiting
204 enrolled

Postoperative Nausea and Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡